Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives

15Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

MCC is a rare but highly aggressive skin cancer. The identification of the driving role of Merkel cell polyomavirus (MCPyV) and ultraviolet-induced DNA damage in the oncogenesis of MCC allowed a better understanding of its biological behavior. The presence of MCPyV-specific T cells and lymphocytes exhibiting an ‘exhausted’ phenotype in the tumor microenvironment along with the high prevalence of immunosuppression among affected patients are strong indicators of the immunogenic properties of MCC. The use of immunotherapy has revolutionized the management of patients with advanced MCC with anti-PD-1/PD L1 blockade, providing objective responses in as much as 50–70% of cases when used in first-line treatment. However, acquired resistance or contraindication to immune checkpoint inhibitors can be an issue for a non-negligible number of patients and novel therapeutic strategies are warranted. This review will focus on current management guidelines for MCC and future therapeutic perspectives for advanced disease with an emphasis on molecular pathways, targeted therapies, and immune-based strategies. These new therapies alone or in combination with anti-PD-1/PD-L1 inhibitors could enhance immune responses against tumor cells and overcome acquired resistance to immunotherapy.

Cite

CITATION STYLE

APA

Zaggana, E., Konstantinou, M. P., Krasagakis, G. H., de Bree, E., Kalpakis, K., Mavroudis, D., & Krasagakis, K. (2023, January 1). Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives. Cancers. MDPI. https://doi.org/10.3390/cancers15010103

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free